 Kazia Therapeutics Ltd ASX:KZA, NASDAQ:KZIAs investigational drug paxalisib is playing a role in PNOC022, a multi-drug phase II study in DIPG and diffuse midline gliomas, that has been initiated at the University of California, San Francisco, with the first patient enrolled to the study. Diffuse intrinsic pontine glioma DIPG is the most common of a group of childhood brain cancers known as diffuse midline gliomas DMGs. 